Liquid Biopsies

Grail – A Pure-Play Stock For Cancer Blood Testing

Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an Initial Public Offering (IPO). Since we’re long Guardant (GH) given […]

A Liquid Biopsy Stock That’s Going Places

The so-called “cure for cancer” isn’t one magical treatment that may or may not be secretly hidden from everyone as part of a vast conspiracy by big pharma. Today’s spray-and-pray approach to cancer treatment has varying degrees of success targeting the over 200 types of cancer, each instance of which is unique to the patient. […]

ArcherDX Promises Precision Oncology For All

Trying to monitor what’s happening in the disruptive technology space is a difficult task, especially in the broad area of life sciences. We try to keep tabs on any IPO which dabbles in any of the 60 disruptive technology themes we research here at Nanalyze. Usually, we’ll have come across a company prior to their […]

8 Companies Developing Liquid Biopsy Cancer Tests

Cancer blood tests, or “liquid biopsies” as they are called, promise to be a huge niche in molecular diagnostics (MDx). Cowen & Co estimates that using DNA blood tests for cancer screening will be a $10 billion a year market in just 4 years. Illumina just announced that they are developing a universal blood test to identify early-stage cancers in people […]